Hydrogel testing is a bottleneck measured in days. A researcher in a lab coat manually measures a sample's swelling, degradation, and absorbency under load, then waits. For a material used in everything from drug delivery and wound dressings to contact lenses and cosmetics, this manual pace is a drag on a $5 billion polymer lab market [GelTech Labs, retrieved 2024]. GelTech Labs, a San Diego startup, is betting a robotic instrument called Carousel can automate that wait away.
Founded in 2023, GelTech has raised approximately $600,000 in early funding and filed two patents, according to founder Sinan Golhan [MedTech 101 podcast, 2024-2025]. The company, which employs between two and ten people, is preparing to unveil its platform at the SLAS2026 conference in January [SelectScience, Jan 2026]. Its bet is simple: replace a tedious, error-prone human task with a purpose-built machine.
The Robotic Wedge
Carousel is not a generic lab robot. It is a hardware and software platform designed specifically for the three core tests of hydrogel characterization: swelling, degradation, and absorbency-under-load (AUL) [GelTech Labs, retrieved 2024]. The company claims the device, which resembles a large printer, can run these tests with about seven times the throughput of a human operator while reducing the cost per test by roughly ten times [MedTech 101 podcast, 2024-2025]. The target customer is any R&D lab working with polymers and hydrogels, a list that spans pharmaceuticals, medical devices, agriculture, energy, food, and consumer products [GelTech Labs, retrieved 2024]. The wedge is specificity. While other automation tools exist, GelTech argues none are built from the ground up for this particular, high-volume analytical workflow.
Founder-Led R&D
The company is led by solo founder Sinan Golhan, whose background includes leading research and development at Harvard and UC San Diego [F6S, 2024]. In a podcast interview, Golhan cited a family experience with cancer as a driving motivation for the work [MedTech 101 podcast, 2024-2025]. The early team includes employee Alexander Kraus and advisor Mehmet Asik [F6S, 2024]. This structure presents a classic deeptech profile: a technically focused founder, early intellectual property development, and a product still seeking its first commercial validations. The upcoming SLAS conference debut will be a critical test of market interest.
The Validation Gap
The core of GelTech's proposition rests on performance claims that, while compelling, are not yet backed by public customer case studies or third-party validation. The company's materials describe a vast addressable market impacting over $30 billion in end products [LinkedIn, 2024-2025], but do not name a single paying lab. For a hardware-centric business selling into cautious, regulated industries like pharma and medtech, this is the central hurdle. The risks are straightforward:
- Commercial proof. The leap from a prototype with filed patents to a product with purchase orders in regulated R&D environments is significant. Labs require rigorous validation data before adopting new equipment.
- Competitive response. While GelTech positions Carousel as a first-of-its-kind tool, established lab automation giants like Thermo Fisher Scientific or Agilent could develop similar capabilities if the market proves sizable.
- Execution scale. As a small, founder-led team, GelTech must simultaneously refine its hardware, build a sales channel, and navigate complex procurement cycles. Its ~$600,000 in angel funding provides runway, but scaling hardware is capital intensive.
The rebuttal, per Golhan, is in the economics. A 10x cost reduction is a powerful argument for any lab manager scrutinizing budgets. If the performance claims hold in real-world settings, the value proposition becomes difficult for cost-conscious R&D departments to ignore.
The Next Twelve Months
The timeline is now concrete. The SLAS2026 unveiling in January provides a launch platform and a deadline. Success in the next year will be measured not by conference buzz, but by the conversion of that interest into paid pilot programs with named customers. GelTech's ~$600,000 angel round gives it room to operate, but the path to a Series A will require demonstrating that labs are willing to swap manual processes for its automated Carousel. For investors watching the deeptech lab automation space, the question is whether GelTech can translate its technical wedge into a commercial one before larger players decide this niche is worth their time.
Sources
- [F6S, 2024] GelTech Labs - Automating hydrogel testing | https://www.f6s.com/company/geltech-labs
- [GelTech Labs, retrieved 2024] GelTech Labs - Automate Biomaterials R&D | https://www.geltechlabs.com/
- [LinkedIn, retrieved 2024] GelTech Labs | https://www.linkedin.com/company/geltechlabs
- [MedTech 101 podcast, 2024-2025] Revolutionizing Hydrogel Testing: Geltech's Breakthrough in MedTech Innovation | https://www.youtube.com/watch?v=uu-RgRxT9qg
- [SelectScience, Jan 2026] GelTech Labs to unveil breakthrough hydrogel testing automation platform at SLAS2026 | https://www.selectscience.net/article/geltech-labs-to-unveil-breakthrough-hydrogel-testing-automation-platform-at-slas2026